Triflupromazine
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a600010 |
ATC code | N05AA05 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 146-54-3 Y |
PubChem (CID) | 5568 |
IUPHAR/BPS | 4330 |
DrugBank | DB00508 N |
ChemSpider | 5367 N |
UNII | RO16TQF95Y N |
KEGG | D00390 N |
ChEBI | CHEBI:9711 N |
ChEMBL | CHEMBL570 N |
ECHA InfoCard | 100.005.158 |
Chemical and physical data | |
Formula | C18H19F3N2S |
Molar mass | 352.418 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
NY (what is this?) (verify) |
Triflupromazine (Vesprin) is an antipsychotic medication of the phenothiazine class. Among different effects of triflupromazine indication for use of this drug is severe emesis. Due to its potential side effects (triflupromazine has higher risk for side effects than many other antipsychotics) it is not gold standard in antiemetic therapy.
Serious side effects of triflupromazine can be akathisia and tardive dyskinesia as well as the rare, but potentially fatal, neuroleptic malignant syndrome.
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
| |||||||||||||||||
|
D1-like |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D2-like |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Receptor (ligands) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (inhibitors) |
| ||||||||||||||
Enzyme (inhibitors) |
| ||||||||||||||
Others |
|
Classes |
|
---|---|
Antidepressants (TCAs and TeCAs) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Others |
|
This article is issued from Wikipedia - version of the 3/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.